Episode 33: Novartis

In this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention.

We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’ll learn how visionary leaders, bold pipeline bets, and a focus on precision medicine shaped Novartis into a global powerhouse.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Novartis #BiotechPodcast #DrugDiscovery #Gleevec #CAR_T #GeneTherapy #OncologyInnovation #PharmaStrategy #PetriDishPerspectives #HealthcareInnovation #PrecisionMedicine #LifeSciences #BiotechResearch

Chapters

• 1:25 Founding Story
• 4:40 Strategic Reinvention
• 9:32 Scientific DNA
• 13:59 People Who Made Their Mark
• 17:11 Lessons from Novartis
• 18:47 Commercial Strategy & Digital Backbone
• 20:44 Recent Challenges & Future Outlook

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

This is the story of Novartis, a Swiss-born powerhouse that has continuously pruned, rebuilt, and evolved itself around a central, challenging thesis: become the world’s leading pure-play innovative medicines company.1

In an industry where massive diversification is the norm—where competitors maintain consumer health, generics, and medical device divisions—Novartis has spent a decade surgically stripping away everything that isn't high-risk, high-reward drug development. This radical focus is their biggest gamble, but also their ultimate differentiator.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

SECTION 1: ORIGINS – From Dyes to Drugs

Let’s rewind all the way back to 1990s. The Novartis we know today didn’t start as one company; it came from the massive $30 billion merger of two giants in 1996: Ciba-Geigy and Sandoz.2 Both were Swiss firms, steeped in history, tracing their roots back to the mid-1800s in Basel, initially focused on chemicals, dyes, and agricultural products.3

• Ciba-Geigy's Roots: Stemmed from Ciba (synthetic dyes) and Geigy (chemicals and dyes).4 They expanded heavily into agrochemicals and pharmaceuticals over the 20th century.5
• Sandoz's Roots: Founded in 1886, Sandoz rapidly moved into pharmaceuticals, producing drugs like the fever-controlling antipyrine and, famously, isolating ergotamine for migraines.6 The company later became a global leader in immunosuppression with the introduction of Sandimmun (Cyclosporine) in 1982.7

The 1996 merger, overseen by key leaders like Alex Krauer (Ciba-Geigy) and Daniel Vasella (Sandoz, who became the first CEO of Novartis), created one of the world's largest life science companies.8 More importantly, it was the first decisive step in a multi-decade pivot away from industrial chemicals and toward high-impact healthcare. The new company's name, Novartis, derived from novae artes, meaning "new skills," perfectly signaled its intent to modernize.9

SECTION 2: THE STRATEGIC REINVENTION – The Vas Narasimhan Era (4.5 Minutes)

The theme of focus would become central to Novartis's identity, but this process accelerated dramatically under the leadership of current CEO Vas Narasimhan, who took the helm in 2018.10 Narasimhan, a physician by training, formalized the strategy of becoming a pure-play innovative medicines company, executing what became known as the "string of pearls" divestitures.

A Decade of Portfolio Surgery:

Year | Divestiture/Transaction | Rationale
2014 | Sold Animal Health to Eli Lilly; Swapped Vaccines with GSK for GSK’s Oncology portfolio | Exit low-margin, non-core businesses; Gain core oncology assets.
2019 | Spun off Alcon | Alcon, the massive ophthalmology device division, was too large and capital-intensive, diluting the focus on innovative drugs.
2023 | Spun off Sandoz (Generics) | Sandoz was a separate business with low growth and different capital needs. The spin-off completed the transition to a high-margin, R&D-driven, pure-play model.

Each move was deliberate portfolio surgery meant to eliminate complexity, increase operating margins, and concentrate capital on the five core therapeutic areas: Cardiovascular, Immunology, Neuroscience, Solid Tumors, and Hematology.11 This strategy is highly unusual for big pharma, which traditionally uses diversified cash flow to weather R&D cycles. Novartis chose concentration over safety.

SECTION 3: SCIENTIFIC DNA – Betting on the Mechanism 

Novartis’s success is built around a central scientific thesis: high-risk, high-reward, mechanism-driven drug development championed through the Novartis Institutes for BioMedical Research (NIBR). The foundation for this culture was established in the early 2000s under leaders like Dr. Paul Herrling, who was instrumental in integrating the research organizations of Sandoz and Ciba-Geigy and overseeing the development of key projects like Gleevec.12

1. Oncology Leadership: The Gleevec Paradigm

The company’s defining moment was the 2001 launch of Gleevec (Imatinib) for Chronic Myeloid Leukemia (CML). Gleevec was not just a drug; it was a revolution. It was one of the first successful, orally available small molecules to target a specific genetic defect (the BCR-ABL fusion protein). Gleevec validated the entire concept of precision oncology and targeted therapy, reshaping cancer treatment from broad chemotherapy to molecularly driven intervention.

Novartis continues this legacy with next-generation assets:

• Kisqali (Ribociclib): A potent CDK4/6 inhibitor that continues to show survival benefits in breast cancer.
• Pluvicto (Lutetium-177 vipivotide tetraxetan): A radioligand therapy representing the next wave of precision treatment for metastatic prostate cancer.13

2. Radioligand Therapies (RLTs): The Signature Bet14

Under Narasimhan, Novartis went all-in on Radioligand Therapies (RLTs), which combine a targeting molecule (like a peptide) with a radioactive isotope.15 The drug effectively acts as a tiny, targeted missile system. This became a signature platform through the 2018 acquisitions of:

• Advanced Accelerator Applications (AAA): Acquired for $3.9 billion, bringing the approved RLT Lutathera (for neuroendocrine tumors) into the fold.16 AAA was a CERN spin-off led by Stefano Buono.17
• Endocyte: Acquired for $2.1 billion, providing the rights to the prostate-specific membrane antigen (PSMA)-targeting candidate that became Pluvicto.18

3. Cell and Gene Therapy: Early Movers

Novartis was one of the earliest movers in advanced therapeutics, demonstrating a long-term vision under the leadership that drove the formation of NIBR:19

• Kymriah (Tisagenlecleucel): The first FDA-approved CAR-T therapy (2017). This cemented Novartis as a leader in a revolutionary, though complex, manufacturing space.
• Zolgensma (Onasemnogene abeparvovec): One of the most famous gene therapies in the world for Spinal Muscular Atrophy (SMA). The drug’s development was driven by the acquisition of AveXis for $8.7 billion in 2018.20

The story of Novartis's transformation is less about market forces and more about the vision and relentless execution of specific leaders who dared to break the Big Pharma mold.

SECTION 4: People who made their mark with Novartis

1. Dr. Daniel Vasella: The Architect of the Conglomerate (1996–2010)

Vasella, a physician, was the inaugural CEO and Chairman who steered the newly merged company.

• 
  The Merger: He was the driving force behind the 1996 merger, seeing a strategic opportunity far beyond local Swiss rivalries.
• The Diversification: Vasella built Novartis into the diversified healthcare conglomerate it was for over a decade, integrating everything from the Sandoz generics arm to the Gerber baby food company. He famously defended the generics business, recognizing its societal value and cash flow strength.
• The Gleevec Bet: Crucially, he oversaw and championed the development and launch of Gleevec, the drug that fundamentally defined the company's commitment to high-risk, high-reward precision medicine.
  
  

2. Dr. Paul Herrling: The Builder of the Research Culture

Dr. Herrling, as Head of Corporate Research, was instrumental in creating the modern research culture that delivered Gleevec and subsequent breakthroughs.

• 
  NIBR Creation: He was a key figure in establishing the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, in 2002, unifying the company's global research network and fostering a science-first culture.
• Global Health Focus: He drove the creation of the Novartis Institute for Tropical Diseases (NITD) in Singapore, demonstrating an early commitment to neglected global health issues like malaria and dengue fever, a hallmark of the company's early ethos.
  
  

3. Dr. Vas Narasimhan: The Pure-Play Surgeon (2018–Present)

Narasimhan took the framework Vasella created and reversed the diversification strategy.

• 
  The Pivot: He led the aggressive divestiture of non-core assets (Alcon, Sandoz) to create the focused "Innovative Medicines" company.
• Platform Leader: Trained as a physician, Narasimhan has strategically championed new technological platforms, making massive, early bets on Radioligand Therapies (RLTs) and Gene & Cell Therapy, pushing the company to acquire the core technologies to own the end-to-end development process.
  
  

SECTION 5: LESSONS FROM NOVARTIS – The Power of Disciplined Focus

The most valuable lesson drawn from the Novartis story is the Power of Disciplined Focus.

• Conglomerate Trap Avoidance: Many large conglomerates (like its predecessor firms) suffer from complexity, slow decision-making, and diluted R&D budgets. By shedding non-core assets (Agro, Generics, Eye Care, Vaccines), Novartis eliminated noise and maximized the return on capital invested in core innovative drugs.21
• Capital Allocation: The divestitures freed up tens of billions of dollars, which were immediately redeployed into high-risk, high-reward platforms like RLTs, Gene Therapy, and RNA/siRNA (following the acquisition of The Medicines Company for its cholesterol-lowering drug, Leqvio). This rapid capital recycling is essential for competitive advantage in modern biotech.
• Cultural Alignment: Narasimhan’s strategy also fostered a cultural shift. The company’s identity now rests solely on scientific excellence and breakthrough innovation, attracting top talent who want to work on truly transformative medicines rather than maintaining diversified portfolios.22 The focus is no longer on how many products, but how impactful they are.

SECTION 6: COMMERCIAL STRATEGY & THE DIGITAL BACKBONE

Novartis’s commercial model is focused on leveraging its concentrated portfolio for maximum impact.

• High-Value Therapy Focus: The strategy emphasizes high-priced, high-impact therapies where clinical value can justify premium pricing (e.g., Entresto, Cosentyx, Pluvicto).
• Digital Integration: While not as loud as the pure TechBio firms, Novartis is quietly building a robust digital backbone. They are:
  • Implementing digital-first clinical trials to improve patient recruitment and data collection speed.
  • Leveraging enterprise-wide AI for everything from optimizing manufacturing logistics to personalizing patient engagement and streamlining regulatory filings.
  • Utilizing data-enabled drug design to enhance its NIBR capabilities, learning from past trial data to inform future molecular design, further accelerating the transition from discovery to IND-enabling studies.

SECTION 7: RECENT CHALLENGES AND THE NEXT DECADE

Despite the strategic clarity, Novartis faces intense challenges.23 The pure-play model significantly heightens revenue concentration risk, making the company extremely reliant on the success of a few key blockbusters, such as Entresto and Cosentyx, as they face patent expirations.24

The next decade, however, is being built on the platform bets:

1. Radiopharma Leadership: Establishing a dominant global footprint for Pluvicto and other emerging RLTs.
2. Next-Gen Immunology: Pushing further beyond Cosentyx with new mechanisms to treat inflammatory and autoimmune diseases.
3. Neuroscience Expansion: Leveraging the Roche/Genentech-derived assets and internal NIBR programs to re-establish a presence in complex neuroscience conditions.

Novartis today looks cleaner, sharper, and more ambitious than at any point in its modern history. Its strategy is a master class in corporate evolution, proving that in Big Pharma, shedding the old is sometimes the only way to embrace the future.

CLOSING

Novartis is a rare example of a pharma giant that constantly reinvents itself—from dyes and chemicals to precision medicines, and from sprawling conglomerate to focused innovation house.25 Its story is about identity, resilience, and an ability to evolve at the pace of science.

This has been Petri Dish Perspectives: Biotech Unleashed. I’m your host, Manead.

If you enjoyed this episode, make sure to follow, share, and leave a review.

And stay tuned for the next biotech deep dive. Because the story of science never stops—and neither do we.

References

1. www.wikipedia.org
2. https://www.novartis.com/ 
3. https://endpts.news/ 
4. www.firstwordpharma.com 

© 2025 Petri Dish Perspectives LLC. All rights reserved.